What's in Novan, Inc.'s pipeline?

Novan, Inc. has 19 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 11 in Phase 2, 5 in Phase 1.

Which companies overlap with Novan, Inc.'s portfolio?

No competitive overlap detected.

Subscribe to /feed/company/novan-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Novan, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 11 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SB204 4%	SB204 4%	phase 3	nitric oxide-releasing agent		Dermatology
SB206 12%	SB206 12%	phase 3	Nitric oxide-releasing topical agent	Nitric oxide pathway	Dermatology
SB206 10.3% berdazimer	SB206 10.3% berdazimer	phase 3	Nitric oxide-releasing topical agent	Nitric oxide donor (non-receptor mediated)	Dermatology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Novan, Inc.:

Drug Landscape (2026). Novan, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novan-inc. Accessed 2026-05-15.